Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$11 Mln
P/E Ratio
--
P/B Ratio
0.27
Industry P/E
--
Debt to Equity
--
ROE
-1.32 %
ROCE
-132.33 %
Div. Yield
0 %
Book Value
1.18
EPS
-2.65
CFO
$-524.38 Mln
EBITDA
$-834.79 Mln
Net Profit
$-787.81 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Relmada Therapeutics (RLMD)
| -7.52 | 62.30 | 23.34 | -87.57 | -73.01 | -57.54 | -36.76 |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Relmada Therapeutics (RLMD)
| -87.23 | 18.62 | -84.51 | -29.75 | -17.77 | 747.83 | 52.98 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.73 | 9,808.03 | 20.22 | 23.13 | |
| 284.42 | 8,956.09 | 22.08 | 58.42 | |
| 26.83 | 9,559.25 | -- | -28.77 | |
| 103.38 | 10,030.35 | 30.81 | 14.16 |
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone... (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida. Address: 2222 Ponce de Leon Boulevard, Coral Gables, FL, United States, 33134 Read more
CEO & Director
Dr. Sergio Traversa M.B.A., Pharm.D.
CEO & Director
Dr. Sergio Traversa M.B.A., Pharm.D.
Headquarters
Coral Gables, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Relmada Therapeutics Inc (RLMD) stood at $ 46 Mln as on 31-Dec-24
The share price of Relmada Therapeutics Inc (RLMD) is $0.48 (NASDAQ) as of 23-Apr-2025 14:42 EDT. Relmada Therapeutics Inc (RLMD) has given a return of -73.01% in the last 3 years.
Relmada Therapeutics Inc (RLMD) has a market capitalisation of $ 11 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Relmada Therapeutics Inc (RLMD) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Relmada Therapeutics Inc (RLMD) and enter the required number of quantities and click on buy to purchase the shares of Relmada Therapeutics Inc (RLMD).
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida. Address: 2222 Ponce de Leon Boulevard, Coral Gables, FL, United States, 33134
The CEO & director of Dr. Sergio Traversa M.B.A., Pharm.D.. is Relmada Therapeutics Inc (RLMD), and CFO & Sr. VP is Dr. Sergio Traversa M.B.A., Pharm.D..
There is no promoter pledging in Relmada Therapeutics Inc (RLMD).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Relmada Therapeutics Inc. (RLMD) | Ratios |
|---|---|
|
Return on equity(%)
|
-132.33
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Relmada Therapeutics Inc (RLMD) was $0 Mln.
$0.10
(
